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Abstract
Introduction: Temporary occlusion of the hepatoduodenal ligament leads to an ischemic-reperfusion (IR) injury in the liver.
Levosimendan is a new positive inotropic drug, which induces preconditioning-like adaptive mechanisms due to opening of
mitochondrial KATP channels. The aim of this study was to examine possible protective effects of levosimendan in a rat
model of hepatic IR injury.
Material and Methods: Levosimendan was administered to male Wistar rats 1 hour (early pretreatment) or 24 hours (late
pretreatment) before induction of 60-minute segmental liver ischemia. Microcirculation of the liver was monitored by laser
Doppler flowmeter. After 24 hours of reperfusion, liver and blood samples were taken for histology, immuno- and enzyme-
histochemistry (TUNEL; PARP; NADH-TR) as well as for laboratory tests. Furthermore, liver antioxidant status was assessed
and HSP72 expression was measured.
Results: In both groups pretreated with levosimendan, significantly better hepatic microcirculation was observed compared
to respective IR control groups. Similarly, histological damage was also reduced after levosimendan administration. This
observation was supported by significantly lower activities of serum ALT (pearly = 0.02; plate = 0.005), AST (pearly = 0.02;
plate = 0.004) and less DNA damage by TUNEL test (pearly = 0.05; plate = 0.034) and PAR positivity (pearly = 0.02; plate = 0.04).
Levosimendan pretreatment resulted in significant improvement of liver redox homeostasis. Further, significantly better
mitochondrial function was detected in animals receiving late pretreatment. Finally, HSP72 expression was increased by IR
injury, but it was not affected by levosimendan pretreatment.
Conclusion: Levosimendan pretreatment can be hepatoprotective and it could be useful before extensive liver resection.
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Introduction
The liver is susceptible to numerous conditions associated with
hypoxia or hypoperfusion. During extensive liver resections,
temporary occlusion of the hepatoduodenal ligament – widely
known as Pringle’s maneuver - is often used to control bleeding
[1]. However, this maneuver can lead to ischemic-reperfusion (IR)
injury of the liver. Recently, a total exclusion of the hepatic inflow
is rarely necessary due to more advanced bleeding control and
operative techniques. However, inflow exclusion of the portal
vessels may be unavoidable if unexpected hemorrhage occurs
during traumatic liver injury or transplantation.
A large number of studies investigated various methods how to
attenuate IR injury in the liver. Of those, the most frequently
investigated is ischemic preconditioning (IP), which seems to be
the most effective, too [2], [3]. The hepatoprotective effect of IP
can be detectable in two distinct patterns (two windows of
protection) in terms of time course. The first, which is known as
‘‘early’’ preconditioning lasts for 1–2 hours. The second is usually
referred as ‘‘late’’ preconditioning, and it begins 24 hours
subsequent to the conditioning stimulus and lasts up to 48–72
hours thereafter [4], [5]. A better understanding of the underlying
signaling pathways made it possible to apply various pharmaco-
logical agents to induce hepatoprotection against IR experimen-
tally [6].
Mitochondria play key roles in cellular IR injury, due to their
crucial functions in energy production and programmed cell
death. A dominant factor in mitochondrial damage and subse-
quent dysfunction is the opening of the mitochondrial permeability
transition pores (MPTP) located in the inner membrane of the
organelle [7], [8]. The mitochondrial adenosine triphosphate-
dependent potassium channels (mito-KATP) have critical effect in
regulating mitochondrial volume as well as function [9]. Inhibition
of mito-KATP channels leads to suspension of the protective effect
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of IP, whereas channel-opening chemical compounds can provide
protection against IR injury similar to IP. It is assumed that mito-
KATP may be able to prevent long-term opening of MPTP, thus
preserving the integrity of the mitochondria and ensuring a better
cellular energy status. Based on the above, chemical induction of
mito-KATP opening can be a potential mechanism for pharma-
cological preconditioning [10], [11].
Levosimendan is an inodilator, cardioprotective drug used in
the management of acute heart failure. This agent exerts a positive
inotropic and an anti-stunning effect by increasing calcium
sensitivity of the myocardial contractile elements, as well as a
vasodilatator effect by opening sarcolemmal KATP channels in
vascular smooth muscle cells. Recent studies demonstrated that
levosimendan is able to open the mito-KATP channels, too [12].
These results prompted in vitro and in vivo studies on the anti-
ischemic effect of the drug, suggesting that levosimendan has a
direct cellular protective effect against IR injury [13]. Further,
levosimendan does not reduce splanchnic blood flow in contrast to
other positive inotropic agents, and it has a positive effect on small
bowel and liver perfusion, too [14] [15]. In addition, it was
demonstrated that levosimendan can protect against acute renal
failure in sepsis [16].
Therefore, we aimed to study the protective effect of
levosimendan against liver IR injury in an experimental rat model.
Materials and Methods
Animals
Male Wistar rats, weighing 250–280 g were used in the
experiments (Charles River Hungary Ltd.). The experimental
design was regulated by Act XXVIII of 1998 and Government
Decree 243/1998 (XII. 31), and approved by committee on
Animal Experimentation of Semmelweis University (license
number: 22.1/743/001/2007). The rats were kept on standard
chow and water ad libitum under specific, pathogen-free conditions
at 22–24uC. For 12 hours prior to surgery water was provided
only. Each experiment was started at the same time of the day to
avoid any possible effects of the circadian rhythm.
Pretreatment Protocol
Levosimendan pretreatment was applied 1 or 24 hours before
the induction of liver IR injury to mimic the two distinct patterns
in time for therapeutic effect of surgical ischemic preconditioning.
Levosimendan (SimdaxH, OrionPharma Ltd, Hungary) was
administered as a total dose of 54 mg/kg in 5 cycles (each cycle
for 5 min) dissolved in 5% glucose solution via a polyethylene
catheter placed into the left jugular vein (PolyE Polyethylene
Tubing, Harvard Apparatus, United States). A 10 minutes pause
was held between infusion cycles to create a pattern similar to IP.
Control and sham-operated animals received the vehicle in the
same pattern.
Operative Procedure
Animals were anaesthetized with intraperitoneal injections of
ketamine (75 mg/kg) and xylazine (7.5 mg/kg). Deep anesthesia
was maintained by intravenous administration of 25 mg/kg/h
ketamine and 2.5 mg/kg/h xylazine via a 22-gauge polyethylene
catheter placed into the right jugular vein. Another polyethylene
catheter was inserted into the femoral artery to monitor mean
arterial blood pressure (MAP) and heart rate (HR) (Kent Scientific
Corporation, Torrington, CT, USA). The animals were allowed to
breathe spontaneously during surgery. Intraoperative normother-
mia (36.5–37.5uC) was maintained by a heating pad connected to
a rectal thermometer.
A standardized surgical model was used for assessment of liver
IR damage as described previously [17], [18], [19]. (Figure 1)
Briefly, after median laparotomy and mobilization of the liver,
lobes III, IV, V were subjected to 60 min ischemia by clamping of
the biliovascular trunk using an atraumatic microvascular clip.
Immediately before reperfusion, the shunting lobes (I, II, VI, VII)
were removed, thus reperfusion affected only the post-ischemic
tissue (65–70% of the total hepatic mass). The microcirculation of
lobe V was monitored using laser Doppler flowmeter (LDF)
throughout the ischemic period and the first hour of reperfusion.
During IR periods, the abdomen was covered with a plastic wrap
to minimize uid loss via evaporation. At the end of the first hour of
reperfusion the abdomen was closed and the animals were
returned to their cages. After 24 hours reperfusion, animals were
anesthetized with intraperitoneal injection of ketamine (75 mg/kg)
and xylazine (7.5 mg/kg) and were sacrificed by exsanguinations
via right ventricular puncture, then blood and histological samples
were taken.
Experimental Groups
A total of 55 animals were randomly separated into two main
groups: (E) ‘‘early’’ (pretreatment 1 h before surgery) and (L)
‘‘late’’ (pretreatment 24 h before surgery).
(S) Sham-operated group (n=5): rats were subjected to
glucose pretreatment (as detailed in pretreatment protocol section)
and surgical procedures (as described above), except for induction
of liver ischemia, but including liver resection (lobes I, II, VI, VII).
(CE; CL) Control groups (n=5–5): rats – similarly to the
sham-operated group – were subjected to the surgical procedures
as well as to ‘‘early’’ or ‘‘late’’ levosimendan pretreatment.
(IRE; IRL) Ischemia-reperfusion groups (n=10–10):
animals underwent the entire surgical procedure, including the 60
minutes partial liver ischemia and liver resection followed by 24 h
of reperfusion.
(LE; LL) Levosimendan pretreated groups (n=10–10):
rats received levosimendan 1 h or 24 h prior to liver IR and were
operated similarly to the IR group.
Assessment of Hepatic Microcirculation
Liver microcirculation was evaluated by laser Doppler flowme-
ter (Moor Instruments Ltd, London, UK). The LDF probe was
placed at the same position on lobe V in every experiment. For
characterization of the individual ow graphs, a mathematical
correction was performed as described previously by us. To
compare the flow graphs, the integral of the reperfusion segment
of the graphs (RA: reperfusion area) and the maximal plateau of
the last 10 minutes of the reperfusion (PM: plateau maximum)
were used [20].
Histopathological Analysis
Methods of histopathological analysis were based on our
previous publications [18], [19]. Samples from excised lobes III,
IV, V were fixed in 4% neutral-buffered formalin for 24 hours,
dehydrated and embedded in paraffin. Sections of 3–5 mm
thickness were stained with hematoxylin and eosin (H&E). During
histological evaluation, the following changes were evaluated by an
experienced pathologist: (1) cellular swelling, (2) lipoid degenera-
tion, (3) sinusoidal congestion, (4) tissue hemorrhage, (5) leukocyte
infiltration, (6) necrosis and (7) signs of apoptosis. These
pathological changes were semiquantitatively scored as follows:
0: no alteration, +: ,10% of affected cells, ++: ,50% of affected
cells, +++: .50% of affected cells. Hence, the overall maximum
score was 21. The evaluating pathologist was blinded to the
experiment.
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Immunohistochemical Analysis
Terminal deoxynucleotidyl transferase-mediated dUTP nick
endlabeling (TUNEL) assay was used to further assess extent of
damaged areas. Commercially available kits were used (Chemicon
International Inc, Temecula, CA, USA), and histological slides
were counterstained with hematoxylin (Vector Laboratories,
Burlingame, CA, USA). The size of the demarcated TUNEL
positive areas was evaluated and expressed as a percentage of the
whole section.
Poly(ADP-ribose) polymerase (PARP) activation was measured
by immunohistochemical detection of the enzyme’s product,
poly(ADP-ribose) (PAR) with the use of mouse monoclonal anti-
poly(ADP-ribose) antibody (1:1000, Calbiochem), as described
previously [21]. Immunoreactivity was evaluated in the demar-
cated areas as well as in the surrounding areas; the ratio of PAR
positivity is shown as a percentage value.
Measurement of Serum ALT and AST
Blood samples were centrifuged (1050 g for 2610 min, at room
temperature) and the supernatant was collected. Serum samples
were frozen in liquid nitrogen and stored at 280uC. Alanine
aminotransferase (ALT) and aspartate aminotransferase (AST)
were quantified by standard spectrophotometry using automated
clinical chemistry analyzer (Hitachi 747, Hitachi Ltd, Tokyo,
Japan).
Measurement of Antioxidant Status
Total scavenger capacity in the plasma (blood samples were
centrifuged at 1050 g for 2610 min at 4uC) and liver homogenates
were measured in H2O2/OH
N luminol microperoxidase system
using Lumat LB 9051 luminometer (Lumat; Berthold, Windbad,
Germany) [22]. The chemiluminescence light intensity - given in
relative light units (RLU) - was proportional to the concentration
of free radicals. The results were expressed as a percentage
compared to the background (RLU %). Protein content was
measured using Lowry’s method [23].
Free SH-groups were detected using the Sedlak method based
on Ellmann reaction [24]. The results show the protein-related
reducing power in mmol/L. The H-donating ability, reflecting the
non-protein-bound antioxidant state of the samples, was measured
in the presence of a 1,1-diphenyl-2-picryl-hydrasyl radical at
517 nm using Blois’ method as modified by Bla´zovics et al [25],
[26]. The results were expressed in percentage of inhibition. The
samples’ reducing power (RP) was assessed using Oyaizu’s method
[27]. The changes in absorbance caused by transformation of Fe3+
into Fe2+ were detected at 700 nm and compared with the changes
of ascorbic acid (AA). The spectrophotometric measurements were
carried out with Jasco V-550.
Luminol, microperoxidase, hydrogen peroxide were purchased
from Sigma (St. Louis, MO, USA), the other chemical reagents
were obtained from Reanal Chemical Co. (Budapest, Hungary).
Liver Tissue Viability
Parts of lobe V were frozen in liquid nitrogen and stored at
280uC. Five mm thick cross-sections were made. Slides were
incubated for 30 min at 37uC in nitroblue tetrazolium (NBT,
18 mg/l) and NADH (150 mg/l) reagents (Sigma-Aldrich Inc,
St. Louis, MO, USA) diluted in 0.05 M TRIS buffer (pH 7.6).
Unused tetrazolium reagent was removed by ascending (30%,
60% and 90%), followed by descending concentrations of
acetone [28]. The amount of colored reaction product was
directly proportional to the absolute number of the functional
mitochondrial NADH-dehydrogenase enzyme complex, it could
therefore be used to determine mitochondrial integrity and cell
viability.
Viability was assessed by quantitative evaluation of the reaction.
Ten random fields were microphotographed. The amount of
generated reaction product was determined using Leica Qwin Pro
image analysis software (Leica Microsystems Imaging Solutions
Ltd, Cambridge, UK). The obtained amount was then compared
to the total area. All viewing fields were evaluated separately.
Regarding whole sample, the ratio was calculated as a ten-field-
average and expressed as a percentage of NBT positivity of simple
sham-operated animals.
Heat Shock Protein (HSP) 72 Expression
HSP72 expression of the liver was measured from tissue
homogenate using Western blot analysis [29]. The bands were
visualized by chemiluminescence technique. Detection and
quantitative analysis of results were achieved using ImageJ
software (NIH, Bethesda, MD, USA).
Figure 1. Liver lobes III, IV, V were subjected to 60 min ischemia by clamping of the biliovascular trunk using an atraumatic
microvascular clip (asterix). Immediately before reperfusion, the shunting lobes (I, II, VI, VII) were removed, thus reperfusion affected only the
post-ischemic tissue.
doi:10.1371/journal.pone.0073758.g001
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Statistical Analysis
Values were expressed as means 6 SD. Statistical significance
was determined by one-way analysis of variances (ANOVA)
followed by Scheffer’s post-hoc test. A p,0.05 confidence interval
was considered as statistically significant.
Results
Hemodynamic Parameters
Immediately (within 1 min) after the levosimendan pretreat-
ment, there was a significant decrease in the mean arterial blood
pressure (p = 0.044) and an increase in the heart rate (p = 0.049) as
compared to groups receiving glucose only. The blood pressure
measured directly before the ischemic period was similar to the
initial value in the ‘‘late’’ groups.
Hemodynamic parameters did not change significantly in any of
the experimental groups throughout the 60 minutes of ischemia.
After induction of reperfusion, tachycardia and a considerable
reduction of MAP (pIRE = 0.047; pIRL = 0.033) were observed in
the IR animals (IRE; IRL). 5–10 minutes after the onset of
reperfusion blood pressure normalized slowly, but it did not reach
the pre-ischemic values completely. In contrast, reperfusion did
not cause further significant drop in the blood pressure in the
levosimendan pretreated groups, furthermore, MAP reached the
baseline level at the end of the first hour of reperfusion.
Microcirculation Measured by LDF
Both ‘‘late’’ and ‘‘early’’ levosimendan pretreatments caused
significant improvement (RA: pearly = 0.0012; plate = 0.0010; PM:
pearly = 0.0019; plate = 0.0007) in the microcirculation of the liver
compared with the respective IR groups (Figures 2–3 & Table 1).
Histopathological Analysis
There was no pathological change detectable in the ‘‘early’’
control group (CE), except occasional mild sinusoidal dilatation
(total score: 2.1). In the IR group (IRE), however, necrotic areas,
substantial periportal lymphocyte infiltration and tissue hemor-
rhage were found (total score: 11.6). In the levosimendan
pretreated group (LE) significantly less focal necrosis was seen
(total score: 7.8; p= 0.043). Tissue hemorrhage was not typical and
leukocyte infiltration was less extensive.
In the ‘‘late’’ control group (CL), increased sinusoidal dilatation
and occasional perivascular edema were observed when compared
with the sham-operated and ‘‘early’’ control groups (total score:
4.8). In the IR group (IRL) extensive, predominantly panlobular
necrosis was detected, which was associated with significant
leukocyte infiltration and tissue hemorrhage (total score: 12.3).
The levosimendan pretreated group (LL) was characterized by
focal necrosis, milder tissue hemorrhage and less severe inflam-
matory cell infiltration (total score: 7.9; p= 0.041) (Figure 4).
Immunohistochemical Analysis
After liver injury induced by IR, almost exclusively demarcated
areas of positive cells were observable with TUNEL immunohis-
tochemical staining. After levosimendan pretreatment, however, a
significant reduction of the demarcated areas was seen both in the
‘‘early’’ and the ‘‘late’’ groups, when compared to the corre-
sponding IR groups (pearly = 0.05; plate = 0.034).
Furthermore, PAR-positive area was significantly reduced, too,
after ‘‘late’’ levosimendan pretreatment compared to the ‘‘late’’ IR
group (plate = 0.04) (Table 2).
Measurements of Serum ALT and AST
Serum ALT activity in the IR groups was significantly higher
than the sham-operated groups. However, serum ALT activity was
significantly lower in the levosimendan pretreated groups than the
IR groups (pearly = 0.02; plate = 0.005).
Serum AST activity in the ‘‘late’’ IR group (IRL) was higher
than the ‘‘early’’ IR group (IRE). However, ‘‘late’’ levosimendan
pretreatment substantially reduced serum AST activity
(plate = 0.04) (Figure 5).
Measurement of Antioxidant Status
Free radical concentrations were significantly increased in the
IR groups compared with sham operated and control animals.
‘‘Early’’ levosimendan pretreatment resulted in significantly lower
RLU% values in the serum after 24 hours of reperfusion when
compared with the IR groups (pearly = 0.03).
Levosimendan pretreatment led to a significant improvement in
the reducing power of the serum compared with the IR groups
(pearly = 0.01; plate = 0.03). In case of the liver, the improvement
was significant only with the use of the ‘‘early’’ pretreatment
protocol (pearly = 0.01).
Concentration of free SH-groups was significantly decreased in
the liver in the levosimendan pretreated groups (pearly = 0.02;
plate = 0.03), whereas in serum samples only an improving
tendency could be seen.
The non-protein-bound antioxidant capacity indicator H-
donating ability showed significant improvement in the serum
after ‘‘early’’ levosimendan pretreatment as compared with the IR
groups (pearly = 0.04) (Table 3).
Liver Tissue Viability
In the ‘‘late’’ control group, liver tissue was significantly less
viable then sham-operated animals, and a similar tendency was
observed in the ‘‘early’’ control group (S: 100%; CE: 82%; CL:
Table 1. Microcirculatory data of the liver.
Microcirculatory parameters Experimental groups
‘‘early’’ pretreatment ‘‘late’’ pretreatment
S CE IRE LE CL IRL LL
Reperfusion area (RA) % 95.765 97.3622 23.9612 47.2*66 81.3614 22.8610 55.6*618
Plateau maximum (PM) % 95.665 100624 37.9616 66.8*69 81.8612 28.469 67.1*622
S: sham-operated; CE: ‘‘early’’ control; IRE: ‘‘early’’ ischemia-reperfusion; LE: ‘‘early’’ levosimendan pretreated; CL: ‘‘late’’ control; IRL: ‘‘late’’ ischemia-reperfusion; LL: ‘‘late’’
levosimendan pretreated.
*p,0.05 versus the respective IR group.
doi:10.1371/journal.pone.0073758.t001
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77%). Further, liver tissue turned out to be significantly less viable
in the ‘‘late’’ IR control group compared to the ‘‘early’’
counterpart (IRL: 23%; IRE: 51%; p= 0.0001). Importantly,
levosimendan pretreatment administered 24 hours before surgery
significantly increased the proportion of NBT-positive areas (LL:
42%; plate = 0.003), while ‘‘early’’ administration of levosimendan
a similar effect, too (Figure 6).
HSP72 Expression
In both IR groups a substantial increase in liver HSP72
expression was observed compared with the sham-operated group.
Neither the ‘‘early’’, nor the ‘‘late’’ levosimendan pretreatment
resulted in changes of the IR-induced HSP72 expression pattern
(Figure 7).
Discussion
Liver IR injury develops primarily during transplantation,
traumatic injury or extensive liver resection due to a temporary
occlusion of the hepatoduodenal ligament. Several methods have
been tried to attenuate or prevent IR injury, but no significant
success has been achieved until Murry published a new pioneering
technique called ischemic preconditioning [30]. A better under-
standing of the underlying signaling mechanisms of IR-related
pathological changes opened new perspectives in research focusing
on treatment strategies for IR liver injury.
Levosimendan is a unique positive inotropic molecule in terms it
does not reduce splanchnic circulation as well as it has anti-
ischemic properties by opening mito-KATP channels [15] [31].
Figure 2. Hepatic microcirculation after ‘‘early’’ levosimendan pretreatment. The blood flow of sham-operated (S) and ‘‘early’’ control
group (CE) did not change significantly. There was a decline of the ux in groups subjected to IR (IRE; LE). Levosimendan pretreatment (LE) significantly
improved liver microcirculation compared to the IRE group during reperfusion. Values are expressed as means. * p,0.05 versus IRE group. n = 5 in
sham-operated (S) and control groups (CE); n = 10 in IR (IRE) and levosimendan pretreated groups (LE).
doi:10.1371/journal.pone.0073758.g002
Figure 3. Hepatic microcirculation after ‘‘late’’ levosimendan pretreatment. In the ‘‘late’’ control group (CL) a reduction of blood flow was
observed in comparison to sham-operated animals (S), but the difference was not significant. However, there was a significant decline of the ux in
groups subjected to IR (IRL; LL). Levosimendan pretreatment (LL) caused significant improvement in the microcirculation of the liver compared with
the IRL group. Values are expressed as means. * p,0.05 versus IRL group. n = 5 in sham-operated (S) and control group (CL); n = 10 in IR (IRL) and
levosimendan pretreated group (LL).
doi:10.1371/journal.pone.0073758.g003
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Hence, we examined the effect of levosimendan in a rat liver IR
model.
Microcirculation is a crucial factor in IR liver injury. Changes in
the microcirculatory blood flow usually precede the development
of parenchymal abnormalities [32]. Microcirculatory changes may
prolong ischemic time and enlarge irreversibly damaged areas. In
addition, it can trigger progressive inflammatory response [33].
We demonstrated previously that improvement in microcircula-
tion reduced hepatic injury [20]. Therefore, the quality of tissue
microcirculation may indicate the severity of organ damage and
the efficacy of any intervention. Literature data suggested that
levosimendan improves microcirculatory blood flow of the
splanchnic area in septic rats [34]. In consistent with the above,
our results showed that levosimendan pretreatment applied 1 or 24
hours prior to surgery resulted in highly significant improvement
in liver microcirculation compared with the corresponding IR
groups.
In terms of H&E-stained histological slides, important differ-
ences were detected between the experimental groups. In the IR
groups, large and often confluent areas of necrosis was observed,
which was accompanied by significant hemorrhage and leukocyte
infiltration. Meanwhile the levosimendan pretreated animals
showed dramatically less cell death, which was mostly focal.
Consistently, tissue bleeding was not typical and leukocyte
infiltration was less extensive, too. The moderate tissue damage
of pretreated animals was supported by a significant decrease in
serum ALT and AST activities.
During IR liver injury, cell death is characteristic for
hepatocytes and sinusoidal endothelial cells predominantly.
Theoretically, cell death can happen as oncotic necrosis and
apoptosis. Terminal deoxynucleotidyl transferase-mediated deox-
yuridine triphosphate nick-end labeling (TUNEL) - commonly
used to determine single- or double-strand DNA breaks – typically
characterizes apoptotic cell death. However, DNA degradation
occurs during necrosis, too, especially during IR damage due to
nucleases released from inflammatory cells [35]. Therefore, this
assay is not reliable to demonstrate apoptosis specifically, it is
rather suitable to determine the extent of DNA damage as a
cytotoxic consequence of IR [36]. Consistently, diffuse TUNEL
positive areas were detected in the IR groups. These TUNEL
positive areas corresponded to the extensively damaged parts seen
in H&E-stained slides, where apoptosis and necrosis are likely to
Figure 4. Representative H&E-stained liver sections. In the control groups (A: ‘‘early’’ control; D: ‘‘late’’ control) mild tissue injury and sinusoidal
dilatation were observed. In the IR groups (B: ‘‘early’’ IR; E: ‘‘late’’ IR) confluent necrotic areas were detected accompanied by significant leukocyte
infiltration and tissue hemorrhage. The levosimendan pretreated groups (C: ‘‘early’’ levosimendan pretreatment; F: ‘‘late’’ levosimendan pretreatment)
were characterized by focal necrosis associated with milder tissue hemorrhage and less severe leukocyte infiltration.
doi:10.1371/journal.pone.0073758.g004
Table 2. Immunohistochemical analysis.
Measured parameters Experimental groups
‘‘early’’ pretreatment ‘‘late’’ pretreatment
S CE IRE LE CL IRL LL
TUNEL positivity 0 0 5.760.9 1.260.6 0 15.761.3 1.260.7
in the demarcated area (%)
PAR positivity – – 6.360.8 1.560.3 – 17.361.9 1.660.5
in the demarcated area (%)
S: sham-operated; CE: ‘‘early’’ control; IRE: ‘‘early’’ ischemia-reperfusion; LE: ‘‘early’’ levosimendan pretreated; CL: ‘‘late’’ control; IRL: ‘‘late’’ ischemia-reperfusion; LL: ‘‘late’’
levosimendan pretreated.
doi:10.1371/journal.pone.0073758.t002
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occur. After ‘‘early’’ and ‘‘late’’ levosimendan pretreatment, a
significant decrease was observed in the size of TUNEL positive
areas. These results are supported by literature data showing anti-
apoptotic properties of levosimendan in other organs like the heart
and kidney [37], [38]. Low level of DNA cleavage is supported by
PAR-positivity of the demarcated region as well. PARP activity is a
marker of DNA damage and repair, which is characteristic to
excessive DNA damage [39]. PAR-positivity suggested a signifi-
cantly lower DNA- and cell injury in the ‘‘late’’ levosimendan
pretreated groups.
The ischemic insult leads to sublethal cell injury, which is
exacerbated by acute generation of reactive oxygen species
following reoxygenation. Free radicals cause direct tissue injury
and initiate a number of noxious cellular responses leading to the
formation of proinflammatory mediators and infiltration and
activation of macrophages, neutrophils and lymphocytes, which
may further enhance oxidative stress and tissue injury [40].
Previous studies demonstrated that administration of levosimen-
dan exerts a beneficial effect on immune response and redox-
homeostatsis [2], [41]. We demonstrated that levosimendan
pretreatment decreased the level of free radicals and improve
the antioxidant status of the liver in the ‘‘late’’ and ‘‘early’’ groups,
too. In addition, histopathological analysis showed less severe
inflammatory cell infiltration in the levosimendan pretreated
groups.
Our results suggest that levosimendan pretreatment is associated
with an attenuation hepatocyte damage during and after warm
ischemia. This phenomenon may be a result of pharmacological
preconditioning induced by levosimendan.
Rapidly increased expressions of HSPs are induced by various
cellular injuries – such as IR – which play an important role in
protective mechanisms of IP [42]. HSPs are intra-cellular
chaperones protecting the function as well as the structure of
injured proteins. Kume et al. showed that the induction of HSP72
in the liver contributes to the reduction of IR injury irrespective of
the type of preconditioning [43]. Hence, we decided to determine
the HSP72 expression in the liver. We could not detect, however,
significant differences between the levosimendan pretreated and
the IR groups. Therefore, HSP72 is unlikely to play an important
part in hepatoprotective pharmacological preconditioning induced
by levosimendan.
Figure 5. Serum level of ALT and AST. Ischemic-reperfusion injury
of the liver led to an increase in serum activities of alanine
aminotransferase (ALT) and aspartate aminotransferase (AST).A: Serum
levels of ALT significantly decreased in the levosimendan pretreated
groups (LE, LL) compared to the corresponding IR groups (IRL, IRE) B:
Raised AST activity in the ‘‘late’’ IR group (IRL) were significantly higher
than in the ‘‘early’’ IR group (IRE). ‘‘Late’’ levosimendan pretreatment
significantly reduced the serum activity of AST. Data are shown as
means+SEM, * p,0.05 versus ‘‘late’’ IR group; ¤ ,0.05 versus ‘‘early’’ IR
group; $ p,0.05 versus ‘‘late’’ control group; & p,0.05 versus ‘‘early’’
control group; # p,0.05 versus ‘‘early’’ IR group. n = 5 in sham-
operated (S) and control groups (CE, CL); n = 10 in IR (IRL, IRE) and
levosimendan pretreated groups (LE, LL).
doi:10.1371/journal.pone.0073758.g005
Table 3. Measurement of antioxidant status.
Measurement Sample Experimental groups
S ‘‘early’’ pretreatment ‘‘late’’ pretreatment
CE IRE LE P* CL IRL LL P**
Total scavenger
capacity (RLU%)
serum 4.3861.68 4.462.15 12.0762.77 8.5162.62 0.03 3.7763.03 9.6962.35 6.7163.74 0.06
liver 21.2561.95 28.35618.55 82.15613.24 66.7364.63 0.06 24.3966.74 75.12617.15 56.3467.34 0.07
Reducing power serum (mmol
AA/ml)
– 0.3860.23 0.5460.13 0.7960.20 0.01 1.1360.53 0.6660.34 1.0860.13 0.03
liver (mmol
AA/g prot)
393.6645.3 266.4634.0 148.6641.1 220.1622.5 0.01 317.8616.6 207.4627.5 248.7636.4 0.06
Free SH-groups
(mmol/l)
serum – 0.04360.018 0.02360.007 0.03060.007 0.06 0.04560.006 0.02360.009 0.03460.019 0.07
liver 0.07760.02 0.06360.015 0.04160.011 0.06160.018 0.02 0.05560.008 0.04360.016 0.05160.012 0.03
H-donating ability serum – 64.0168.95 40.6669.38 51.2867.03 0.04 58.0169.20 38.7568.02 47.83611.05 0.08
liver 44.3564.95 40.9466.33 14.7762.61 18.6863.52 0.06 45.3766.96 18.7462.49 23.1364.48 0.07
S: sham-operated; CE: ‘‘early’’ control; IRE: ‘‘early’’ ischemia-reperfusion; LE: ‘‘early’’ levosimendan pretreated; CL: ‘‘late’’ control; IRL: ‘‘late’’ ischemia-reperfusion; LL: ‘‘late’’
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Literature data demonstrate that the activation of the reperfu-
sion injury salvage kinase (RISK) pathway – a common target for
IP - plays an important role in the anti-ischemic and anti-apoptotic
effect of levosimendan [37]. In addition, levosimendan induces
nitric oxide (NO) production [44] and is able to open KATP
channels directly without the activation of the conventional
Figure 6. Liver tissue viability. Nitroblue tetrazolium (NBT) intensity of the ‘‘late’’ and ‘‘early’’ control animals was lower compared to the sham-
operated group (S), but the difference was significant in the ‘‘late’’ category (CL) only. After IR injury, number of functioning mitochondria further
decreased. NBT positivity was significantly lower in the ’’late’’ IR group (IRL) than in the ’’early’’ IR group (IRE). However, ‘‘late’’ levosimendan
pretreatment was able to enhance significantly the number of viable mitochondria. The data are presented as means+SEM. ¤ ,0.05 versus ‘‘early’’
control group; &p,0.05 versus sham-operated group; $ p,0.05 versus ‘‘early’’ IR group; #p,0.05 versus ‘‘late’’ control group; * p,0.05 versus ‘‘late’’
IR group. n = 5 in sham-operated (S) and control groups (CE, CL); n = 10 in IR (IRL, IRE) and levosimendan pretreated groups (LE, LL).
doi:10.1371/journal.pone.0073758.g006
Figure 7. Liver HSP72 expression. A: Representative Western blotting for HSP72 in sham-operated group (S), control groups (CE, CL), IR groups
(IRE, IRL) and levosimendan pretreated groups (LE, LL). B: Quantitative results of Western blotting. A significant increase in liver HSP72 expression was
observed in the IR groups as well as in the levosimendan pretreated groups compared to the sham-operated group. Levosimendan pretreatment did
not result in changes of HSP72 expression pattern. Data are presented as means+SEM, * p,0.05 versus sham-operated group. n = 5 in sham-operated
(S) and control groups (CE, CL); n = 10 in IR (IRL, IRE) and levosimendan pretreated groups (LE, LL).
doi:10.1371/journal.pone.0073758.g007
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preconditioning signaling pathway [45]. The possible roles of NO
and KATP channels are confirmed by examination with 5-HD (a
specific mito-KATP channel blocker) and N
v-nitro-l-arginine
methyl ester (l-NAME, a nonspecific NO synthase inhibitor),
which ceased the beneficial effect of levosimendan [46]. The above
mentioned IP-like effects of levosimendan are related to the
stabilization of the mitochondria. Maintenance of mitochondrial
integrity in hepatocytes is supported by our study, as well. The
NADH-tetrazolium enzymehistochemical analysis showed signif-
icantly better mitochondrial function and a minor damage only of
the energy-balance when we compared ‘‘late’’ pretreatment
animals to the corresponding IR group.
The hepatoprotective effect of levosimendan may also be the
consequence of the hemodynamic effect of the drug. Our results,
however, failed to support this hypothesis due to insufficient data
on hemodynamics We could demonstrate that the applied dose of
levosimendan induced a typical cardiac effect only: an increase in
heart rate and a decrease in blood pressure, similarly to relevant
literature data [47]. Interestingly, reperfusion-induced hypoten-
sion was relatively lower and the restoration of the hemodynamic
parameters was more effective after levosimendan pretreatment
shows that it may be worth conducting further investigations along
these lines.
Levosimendan pretreatment was applied in two therapeutic
time points in order to mimic the time course of protection
following ischemic preconditioning. We found that hepatocellular
injury was more severe in the ‘‘late’’ experimental groups. This
was supported by histological, immunohistochemical analyses as
well as measurements of AST, ALT levels and tissue viability of
the liver. Major perioperative stress may explain this phenomenon
as a consequence of the two-stage operation. Nevertheless, the
‘‘late’’ levosimendan pretreatment resulted in a more significant
improvement in terms of hepatocellular injury as compared with
the ‘‘early’’ treatment. This may be explained by the fact that the
maximal hemodynamic response after administration of levosi-
mendan can be expected at the end of the first or second day [43].
Conclusions
We examined the effect of levosimendan pretreatment in a liver
IR model in vivo. Our results suggest that levosimendan can be
potentially effective in the prevention hepatic IR injury. Further
experiments should also confirm the beneficial effect of levosi-
mendan prior to consolidation of possible application before
extensive liver resection or transplantation in the future.
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